คำอธิบาย
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.
กลไก
Duloxetine inhibits both SERT and NET; sumatriptan activates 5-HT1B/1D receptors, producing overlapping serotonergic stimulation.
ความสำคัญทางคลินิก
FDA labeling for triptans warns of serotonin syndrome risk when combined with serotonergic drugs including SNRIs.
การจัดการ
Use with caution; counsel patients on warning signs of serotonin syndrome and seek immediate medical care if symptoms develop.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.